Lecture 1 min
Un écosystème de startups innovantes
Depuis plus de 130 ans, l'Institut Pasteur ne se contente pas de produire des connaissances scientifiques de premier plan : il les transforme en solutions concrètes pour les patients. Grâce à un écosystème de start-ups innovantes, nous traduisons les découvertes en thérapies accessibles au plus grand nombre.
Comment l’Institut Pasteur fait naître les innovations de demain ?
En fondant sa première spin-off (entreprise créée à partir des connaissances et technologies issues de la recherche) en 1997, l'Institut Pasteur s'est imposé comme un pionnier dans le soutien à l'entrepreneuriat en biotechnologie. Depuis plus de 25 ans, nous accompagnons les jeunes entreprises qui donnent vie aux avancées médicales pour protéger la santé humaine.
À ce jour, l’Institut Pasteur a contribué au lancement ou au développement de plus de 37 start-ups qui exploitent les technologies et le savoir-faire émanant de nos équipes de recherche.
Chacune de ces entreprises porte en elle une part de l'excellence pasteurienne et continue, à sa manière, de répondre à des défis de santé majeurs — qu'il s'agisse de cancérologie, d'immunologie, de maladies infectieuses, ou encore de médecine de précision.
Les start-ups issues de nos laboratoires
Nées au sein des laboratoires de l'Institut Pasteur, ces entreprises construisent aujourd’hui les thérapies et les technologies de demain.
-
Launched: 2025. A spin-off from the Institut Pasteur's laboratories, Enodia Therapeutics develops novel therapeutic approaches targeting DNA repair mechanisms. This represents a promising avenue, with oncology applications.
-
Launched: 2020. AVATAR MEDICAL™ is revolutionizing surgical planning using medical virtual reality. Its solutions allow 3D visualization and exploration of each patient's specific anatomy by physicians prior to surgery.
-
Oncovita develops innovative therapeutic vaccines drawing directly on technologies derived from Institut Pasteur research.
-
Launched: 2010. Core business: investigating Nanofitins for target capture with a view to developing innovative therapeutic imaging solutions.
-
Launched: 2003. Core business: developing and commercializing computer analysis tools to help with therapeutic decision-making.
-
Launched: 2024. Core business: kits to detect and quantify biomarkers for infectious agents.
-
Launched: 2011. Core business: developing rapid dipstick tests to guide diagnosis, particularly for meningitis, dysentery and cholera.
-
Launched: 1999. Core business: developing technologies to operate directly and precisely on DNA.
-
Launched: 2015. Core business: groundbreaking DNA synthesis technology coding any living being.
-
Launched: 2014. Core business: developing therapeutic agents to tackle resistant bacteria.
-
Launched: 1999. Core business: genetic design used to create high-level genetically modified mouse, rat and cell line models for academic and biopharmaceutical researchers.
-
Launched: 1998. Core business: a biopharmaceutical company involved in research and development of new targets and therapies for the treatment of cancer.
-
Launched: 2010. Core business: developing immunotherapies to treat cancer.
-
Launched: 2018. Core business: developing, manufacturing and commercializing neuroprotective and neuroregenerative molecules targeting eye and central nervous system diseases.
-
Okomera, founded in 2020, is a pioneer in the automation and miniaturization of personalized tumor biopsy studies.
-
Launched: 2010. Core business: Providing services for GMP-grade biopharmaceutical quality control tests based on next generation sequencing (NGS) for viral safety and genetic characterization.
-
Launched: 2008. Core business: novel anti-infective, anti-inflammatory and anti-cancer therapeutic solutions.
-
A biotechnology company, co-founded by Truffle Capital and the Institut Pasteur, whose purpose is to develop an effective treatment for SARS-CoV2 and its main variants.
-
Launched: 2003. Core business: viral safety testing of proprietary biotherapeutic proteins, biotherapeutic development, cell banking and immunology support.
-
Core business: developing vaccines based on lentiviral vectors (cancer, HIV) in the fields of immunization and immunotherapy.
-
Core business: working towards the development of an mRNA-expressed pediatric dengue vaccine.
Notre équipe pluridisciplinaire est à l’écoute de votre projet industriel
Main dans la main avec nos chercheurs et nos experts, améliorez la santé de tous.